Healthcare Jun 02, 2021 10:03 AM (GMT+8)
On the evening of June 1, at the 26th annual meeting of the European hematology Association (EHA 2021), Baiji Shenzhou announced the BTK inhibitor bayattse ®（ The latest data of the head-to-head global phase 3 clinical study on the treatment of relapsed or refractory (R / R) chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) patients compared with the first generation drug ibutinib.
According to the interim analysis, at a median follow-up of 15 months, zebtinib achieved a higher orr (78.3% vs 62.5%, P = 0.0006), while for patients with poor prognosis of 17p -, the orr advantage was more obvious (83.3% vs. 53.8%). At the same time, zebtinib showed a superior 12-month PFS (95% vs 84%, P = 0.0007) and significantly reduced the risk of disease progression by 60%. In terms of safety, patients treated with zebutinib had a lower risk of atrial fibrillation or flutter events (2.5% vs 10.1%, P = 0.0014). Interim analysis of this head-to-head study showed significant improvements in efficacy and safety of zebtinib compared with ibotinib.
Currently, zebutinib has been approved in the United States, Canada and other international markets. In China, it was approved for marketing in June last year to treat MCL and CLL / SLL patients who have received at least one treatment in the past.
This text is a result of machine translation.